Document:

Unassociated Document

    
      
        EXHIBIT
10.33

        

        [***]
Represents material information which has been redacted and filed separately
with the Commission pursuant to a request for confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

         

      

    

    
      
        
          	 	AMENDMENT NO. 1 TO FIRST
      FIT-CROWN DISTRIBUTION	 
	 	

                  AND
      LICENSE AGREEMENT

                	 
	 	 	 

        

      

    

    

    THIS AMENDMENT NO. 1 TO FIRST
FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT (this “Agreement”) is made
as of February 16, 2010 (the “Amendment No. 1 Effective
Date”) by and among Remedent, Inc., a Nevada corporation (“Remedent Nevada”),
Remedent N.V., a Belgian corporation (“Remedent Belgium”,
and together with Remedent Nevada, “Remedent”), and
Den-Mat Holdings, LLC, a Delaware limited liability company (“Den-Mat”).

     

    WHEREAS, Den-Mat and Remedent
have entered into that certain First Fit-Crown Distribution and License
Agreement dated as of June 3, 2009 (the “2009 Agreement”) relating to the
marketing, distribution, licensing and sale of the First Fit-Crown Products (as
such term is defined in the 2009 Agreement); and

     

    WHEREAS, Den-Mat wishes to
purchase from Remedent, and Remedent wishes to sell to Den-Mat, all of the
Intellectual Property (as defined in the 2009 Agreement) previously licensed to
Den-Mat pursuant to the 2009 Agreement; and

     

    WHEREAS, Den-Mat and Remedent
wish to amend the 2009 Agreement as hereinafter provided;

     

    NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Remedent and
Den-Mat hereby agree as follows.

     

    1. Defined
Terms.

     

    Capitalized
terms used herein without definition shall have the respective meanings given to
them in the 2009 Agreement.

     

    2. Purchase
of Intellectual Property.

     

    2.1 Purchase and
Sale.  Notwithstanding anything contained in the 2009 Agreement
to the contrary, Remedent hereby sells, assigns and transfers to Den-Mat (the
“IP Sale”),
free and clear of any debts, mortgages, security interests or other liens and/or
encumbrances, all claims, rights, title and interest that Remedent has or may
have in the Intellectual Property owned or used by Remedent that is related to
the Products, including, without limitation, the “First Fit” trade name, and all
registration documents relating thereto, if any (collectively, the “IP”), as set forth in
Schedule 14.1.5 to the 2009 Agreement.  The Parties agree that the IP
Sale includes all rights that Remedent may have or obtain with respect to
Intellectual Property that relates to the Products and which was developed after
the Effective Date of the 2009 Agreement or is developed after the Amendment No.
1 Effective Date.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    2.2 Transfer of
IP.  Remedent represents and warrants that it owns all rights,
title and interest in and to the IP, free and clear of all debts, mortgages,
security interests or other liens and/or encumbrances, and that it has not
entered into any prior agreements with third parties that would preclude it from
conveying the rights granted herein.  Remedent will cooperate with
Den-Mat and take all steps necessary to effectuate the transfer of the IP to
Den-Mat, including without limitation, executing and delivering such assignment
and other documents as Den-Mat or its counsel may reasonably request to
effectuate the IP Sale.  Remedent agrees to cooperate with Den-Mat in
executing all documents and doing all things that Den-Mat considers necessary or
desirable to further the assignment of the IP to Den-Mat, including executing
any other assignments or other instruments required by the USPTO or other
registries.  Remedent’s obligation hereunder shall survive the closing
of the IP Sale.

     

    2.3 Purchase
Price.  In consideration of the transfer and assignment of the
IP, and of Remedent’s other undertakings and obligations hereunder, Den-Mat
shall pay Remedent the sum of Two Million Eight Hundred Fifty Thousand
($2,850,000.00) Dollars (the “Cash Component”) and
contingent capital payments in accordance with Section 2.4 below (the “Contingent Payments”
and, together with the Cash Component, the “Purchase
Price”).  An advance of $75,000.00 against the Cash Component
shall be paid to Remedent upon execution of this Amendment, which amount shall
be promptly refunded to Den-Mat if the IP Sale is not consummated by March 15,
2010.  Provided that the IP Sale is consummated, the balance of the
Cash Component shall be paid as follows:

     

    (a)  $50,000.00 upon delivery
by Remedent to Den-Mat of a working prototype of the First Fit
crown;

     

    (b)  $525,000.00 on or before
March 15, 2010;

     

    (c)   $700,000.00 on
June 30, 2010;

     

    (d)   $500,000.00 on
December 31, 2010;

     

    (e)   $500,000.00 on
June 30, 2011;

     

    (f)    $500,000.00
on December 31, 2011.

     

    2.4 Contingent
Payments.  For each sale of Products, Den-Mat shall pay to
Remedent a contingent capital payment (each, a “Contingent Payment”) equal to
[***] percent of Den-Mat’s
Net Revenues generated by the sale of the Products.  For purposes
hereof, “Net Revenues” shall mean all revenues received by Den-Mat from sales of
the Products, net of any returns and allowances, freight, sales taxes, rebates
and customary trade discounts.  A sale shall be deemed to have been
made by Den-Mat at the time the related revenue is recognized by Den-Mat for its
internal accounting purposes (in accordance with GAAP).  Within thirty
(30) days after the end of each calendar quarter, Den-Mat shall deliver to
Remedent a certified statement from an officer of Den-Mat setting forth (a) the
total amount of Den-Mat’s Net Revenues generated by the sale of the Products
during such quarter, and (b) a calculation of the Contingent Payment payable to
Remedent hereunder.  Concurrently with delivering such statement
Den-Mat shall pay to Remedent, the amount of the Contingent Payment set forth on
such statement.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    2.5 Representations and
Warranties.  Remedent hereby certifies to Den-Mat that each of
the representations and warranties made by Remedent in Section 14.1 of the 2009
Agreement is true and correct in all material respects as if made on the date
hereof and as if the transactions contemplated by this Amendment No. 1 were part
of the 2009 Agreement.  In addition, Remedent hereby represents and
warrants to Den-Mat that: (a) Remedent has not sold, assigned, transferred,
encumbered or granted to any Person any rights to the IP, and (b) any rights to
IP that are licensed to Remedent by a third party can be transferred and
assigned to Den-Mat without the consent or approval of any third party or, if
such consent or approval is required, Remedent will have obtained it prior to
payment of the first installment of the Purchase Price.  Den-Mat
hereby certifies to Remedent that each of the representations and warranties
made by Den-Mat in Section 14.2 of the 2009 Agreement is true and correct in all
material respects as if made on the date hereof and as if the transactions
contemplated by this Amendment No. 1 were part of the 2009
Agreement.

     

    3. Additional Amendments to 2009
Agreement.  The following provisions of the 2009 Agreement are
hereby amended as follows:

     

    3.1 Sections
2, 3.1, 3.4, 3.5.2, 4, 5, 6, 7, 9, 10.1, 16.1.3, 16.1.4, 16.1.5, 16.2.4, 18.4
and 18.6 are hereby deleted in their entirety.

     

    3.2 Section
3.3 is hereby amended to delete the words “In connection with the licenses
granted to Den-Mat pursuant to Section 3.1” in the
1st
and 2nd lines and to substitute, in lieu thereof, the words “In connection with
the IP Sale”.

     

    3.3 Section
3.5.1 is hereby amended and restated in its entirety to read as
follows:

     

    “Ownership of Intellectual
Property.  Den-Mat shall have the sole and exclusive right to
apply for, prosecute, obtain and enforce all rights, grants, registrations,
orders or proprietary interests of any nature, including, without limitation,
patents, copyrights, industrial design and trademark and service mark
registrations and any other registrations or grants of rights that are analogous
thereto in any and all countries throughout the world in respect of the IP,
including, without limitation, any Intellectual Property related to the Products
developed by Remedent after the Amendment No. 1 Effective Date, which shall be
promptly transferred to Den-Mat.   At Den-Mat’s request and cost,
and for the benefit of Den-Mat, Remedent  shall apply for, prosecute,
obtain and enforce all rights, grants, registrations, orders or proprietary
interests of any nature, including, without limitation, patents, copyrights,
industrial design and trademark and service mark registrations and any other
registrations or grants of rights that are analogous thereto in any and all
countries throughout the world, and take such other actions as Den-Mat may
reasonably request to protect such Intellectual Property.  In the
event Remedent fails to take any action reasonably requested by Den-Mat as
described in the preceding sentence (a) Den-Mat may take such action, (b)
Remedent hereby authorizes Den-Mat to take any such action in its name, and (c)
Remedent shall provide such assistance as Den-Mat may reasonably request in
connection therewith.  Each of Den-Mat and Remedent shall take such
actions as the other may reasonably request to implement the provisions of this
Section 3.5.1 with respect to any particular Intellectual
Property.”

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    
 

    3.4 The
introductory paragraph of Section 8.1 is hereby amended and restated to read as
follows:

     

    “Remedent’s Marketing
Support.  Remedent shall develop and implement commercially
reasonable sales and marketing support to the Den-Mat sales
effort.  Any materials developed by Remedent will be the sole and
exclusive property of Den-Mat.  Remedent shall use its commercially
reasonable efforts to provide the following support (all of which, including the
selection of vendors utilized, shall be subject to Den-Mat’s reasonable
approval) for Den-Mat’s sales and marketing efforts:”

    

    The
remainder of Section 8.1 (clauses (a) – (p)) shall remain
unchanged.

    

     

    3.5 Section
13.2.1 is hereby amended to delete clause (c) thereof.

     

    3.6 Section
16.2.5 is hereby amended to provide that, concurrently with the execution of
this Amendment, Remendent shall deliver to Den-Mat revised Non-Competition
Agreements in the form approved by Den-Mat duly executed by Guy De Vreese and
Evelyne Jacquemyns.

     

    3.7 Section
18.3 is hereby amended by adding the phrase “occurring prior to the Amendment
No. 1 Effective Date” at the end of the first sentence thereof and again in the
second sentence thereof after the phrase “Intellectual Property claim or
judgment,” and prior to the phrase “then Remedent...”

     

    3.8 Section
20.14 is hereby amended to add at the end thereof, after the words “First-Fit
Technology,” the following: “unless Den-Mat agrees to include the Net Revenues
generated by the sale of such competing products in the calculation of the
Contingent Payment.”

     

    3.9 The
definition of “Confidential Information” in Schedule 1 is hereby amended to
provide that all confidential or proprietary information relating to the First
Fit Technology shall be treated as being Den-Mat’s Confidential Information for
purposes of the 2009 Agreement, notwithstanding the exclusions contained in
clauses (b), (c) and (d) of Section 17.1.2.

     

    4. Miscellaneous.

     

    4.1 Binding
Effect.  This Amendment shall be binding upon and inure to the
benefit of the Parties and their respective successors and permitted
assigns.  Except as modified hereby, the 2009 Agreement shall remain
in full force and effect.  

     

    4.2 Headings.  The
headings contained in this Amendment are for reference purposes only and shall
not in any way affect the meaning or interpretation of this Agreement.

     

    4.3 Counterparts.  This
Amendment may be executed in one or more counterparts, all of which will be
considered one and the same agreement and will become effective when one or more
counterparts have been signed by each of the Parties and delivered to the other
Parties, regardless of whether all of the Parties have executed the same
counterpart.  Counterparts may be delivered via facsimile, electronic
mail (including pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes. 

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    4.4 Governing
Law.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES SHALL BE GOVERNED BY, CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW
RULE THAT WOULD CAUSE THE APPLICATION OR THE LAWS OF ANY JURISDICTION OTHER THAN
THE INTERNAL LAWS OF THE STATE OF NEW YORK TO THE RIGHTS AND DUTIES OF THE
PARTIES.

     

    4.5 Den-Mat
Option.  In consideration of the advance being made by Den-Mat
to Remedent concurrently herewith, in accordance with Section 2.3(a) of this
Amendment, and other good and valuable consideration, the receipt and
sufficiency whereof are hereby acknowledged, Remedent hereby grants to Den-Mat
an option to enter into this Amendment at any time during the thirty (30) day
period beginning on the Amendment No. 1 Effective Date (the “Option
Period”).  Remedent agrees that it may not revoke or rescind its
execution and delivery of this Amendment prior to the end of the Option Period,
and that if Den-Mat delivers (by fax, email or personal delivery) a
counter-signed copy of this Amendment on or before the last day of the Option
Period, this Amendment shall then become fully binding upon and enforceable
against the parties hereto with effect from the Amendment No. 1 Effective
Date.     

     

    

     

    [remainder
of page intentionally left blank; signature page follows]

     

     

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    IN
WITNESS WHEREOF, Remedent Nevada, Remedent Belgium and Den-Mat, by their
respective authorized representatives set forth below, have signed this
Amendment No. 1 as of the Amendment No. 1 Effective Date.

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	

                                    REMEDENT,
      INC.

                                    “Remedent
      Nevada”

                                     

                                  	 	 	

                                    REMEDENT,
      N.V.

                                    “Remedent
      Belgium”

                                  	 
	By:    	
                                     

                                  	 	By:  	
                                     

                                  	 
	 	 	 	 	 	 
	Name: 	
                                     

                                  	 	Name: 	
                                     

                                  	 
	 	 	 	 	 	 
	Title:	
                                     

                                  	 	Title: 	
                                     

                                  	 

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

    

    
      
        
          
            
              	

                      

                        DEN-MAT
      HOLDINGS, LLC

                        “Den-Mat”

                      

                       

                    	 	 	

                       

                    	 
	By:    	
                       

                    	 	 	
                       

                    	 
	 	 	 	 	 	 
	Name: 	
                       

                    	 	 	
                       

                    	 
	 	 	 	 	 	 
	Title:	
                       

                    	 	   	
                       

                    	 

            

          

        

      

    

    

    

    
      
        
        

      

      
        6Unassociated Document

    
      Exhibit
10.34

       

      [***]
Represents material information which has been redacted and filed separately
with the Commission pursuant to a request for confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

    

    
    

     

    
      
        	 	AMENDMENT
      NO. 2 TO AMENDED AND RESTATED 	 
	 	      
                DISTRIBUTION,
      LICENSE AND MANUFACTURING

              	 
	 	AGREEMENT
      (GLAMSMILE)	 

      

    

    

    THIS AMENDMENT NO. 2 TO AMENDED AND
RESTATED DISTRIBUTION,
LICENSE AND MANUFACTURING AGREEMENT (this “Agreement”) is made
as of February 16, 2010 (the “Amendment No. 2 Effective
Date”) by and among Remedent, Inc., a Nevada corporation (“Remedent Nevada”),
Remedent N.V., a Belgian corporation (“Remedent Belgium”,
and together with Remedent Nevada, “Remedent”), and
Den-Mat Holdings, LLC, a Delaware limited liability company (“Den-Mat”).

     

    WHEREAS, Den-Mat and Remedent
have entered into that certain Amended and Restated Distribution, License and
Manufacturing Agreement dated as of June 3, 2009 (the “Original Agreement”)
relating to the marketing, distribution, licensing and sale of the GlamSmile
Products and the Other Products (as such terms are defined in the Original
Agreement), which Original Agreement has been amended by Amendment No. 1 dated
August 11, 2009 (“Amendment No. 1”)
(the Original Agreement as so amended being referred to herein as the “2009 Agreement”);
and

     

    WHEREAS, Remedent wishes to be
relieved of various obligations under the 2009 Agreement, including, without
limitation, its obligation to supply Products to Den-Mat, and in consideration
thereof, Remedent is willing to relieve Den-Mat of various obligations under the
2009 Agreement, including, without limitation, certain minimum purchase
requirements as well as capital and royalty payments due under the 2009
Agreement; and

     

    WHEREAS, Den-Mat and Remedent
wish to amend the 2009 Agreement to reflect the foregoing as well as certain
other amendments, as hereinafter provided;

     

    NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Remedent and
Den-Mat hereby agree as follows.

     

    1. Defined
Terms.

     

    Capitalized
terms used herein without definition shall have the respective meanings given to
them in the 2009 Agreement.

     

    2. Amendments to 2009
Agreement.  The following provisions of the 2009 Agreement are
hereby amended as follows:

     

    2.1 Section
2.2.1 is hereby amended to delete the last sentence thereof and replace it with
the following sentence:

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    “Notwithstanding
anything else in this Section 2.2.1 to the contrary, Remedent, or its B2C Market
Licensee, may purchase its requirements for GlamSmile Product in the B2C Market
from another Person other than Den-Mat provided that Remedent, or its B2C Market
Licensee, pays a royalty to Den-Mat equal to [***] of the Net Revenue
received by Remedent or its B2C Market Licensee per Unit/Tooth so purchased by
Remedent or its B2C Market Licensee, as applicable.  For purposes
hereof, “Net Revenue” shall mean the amount charged per Unit/Tooth as it is
invoiced to the end customer from Remedent's perspective (e.g., the dentist, group
practice corporation, distributor), net of any returns, discounts, special
pricing, rebates or additional reasonable price deductions.”

     

    2.2 Section
2.2.2 is hereby amended to change all references to “[***]” to read “[***]”.

     

    2.3 Section
2.3.1 is hereby amended to change the words “five (5) countries” in the 14th line to
read “nine (9) countries”.  Remedent and Den-Mat shall meet and confer
prior to February 24, 2010, to specify which markets in the Excluded Markets
Den-Mat shall be appointed as exclusive distributor in accordance with Section
2.3.1.  

     

    2.4 Section
2.5.1 is hereby deleted in its entirety.

     

    2.5 Section
3.1.1 is herby amended to read in its entirety as follows:

     

    “Use of Existing
Intellectual Property in the Territory.  Subject to the terms
and conditions in this Agreement, Remedent hereby grants to Den-Mat a sole and
exclusive (even as to Remedent) transferable and sublicensable right and license
to use within the Territory the Intellectual Property owned or used by Remedent
that is related to the Products as it exists on the Amendment No. 2 Effective
Date.  Notwithstanding the foregoing, (a) Remedent retains the right
to use and license to any Person performing contract manufacturing for Remedent
(concurrently with Den-Mat’s right to use) such Intellectual Property solely in
connection with the manufacture of the Products and for internal product
development related to the Products, (b) this grant shall not include any rights
to the name or trademark ‘Remedent’, or ‘GlamSmile’ and (c) Den-Mat and Remedent
agree that Den-Mat’s right and license to use the Intellectual Property within
the Territory to the B2C Market shall be non-exclusive.  For purposes
of clarity, Den-Mat shall not use the name or trademark ‘GlamSmile’ without the
prior written consent of Remedent and, other than in the B2C Market (subject to
the terms of this Agreement), Remedent shall not use the name or trademark
‘GlamSmile’ in the Territory without the prior written consent of
Den-Mat.  Notwithstanding anything to the contrary in this Agreement,
neither Remedent nor any B2C Market Licensee nor any Affiliate, permitted
successor or assignee of any of the foregoing, shall, directly or indirectly,
make any reference or comparison in its marketing materials or in any
advertising or sales efforts to any Den-Mat product or trademark including, but
not limited to, LumiSmile, Lumineers, Luminate, or Lumitray, without the prior
written consent of Den-Mat.  Likewise, neither Den-Mat nor any
Affiliate, permitted successor or assignee of any of the foregoing shall,
directly or indirectly, make any reference or comparison in its marketing
materials, or in any advertising or sales efforts to any Remedent product or
trademark, including, but not limited to, Remedent or GlamSmile, without the
prior written consent of Remdent, provided, however, that nothing contained
herein shall be interpreted to preclude or prohibit Den-Mat from indicating in
its marketing materials, packaging or otherwise that the Products are based upon
or incorporate Remedent’s Intellectual Property, including without limitation
the GlamSmile Technology.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    2.6 Section
3.4.1 is hereby deleted in its entirety.

     

    2.7 On the
90th
day following the Amendment No. 2 Effective Date, Section 5 shall be deleted in
its entirety without further action by the Parties.

     

    2.8 Section
6.1.2 is hereby deleted in its entirety.  Remedent acknowledges that
no further payments are due from Den-Mat under Section 6, all such payment
obligations having been paid or waived.

     

    2.9 Sections
6.3, 6.4 and 6.5 are hereby deleted in their entirety, and a new Section 6.3 is
added as follows:

     

    “Consulting
Fee.  In consideration of the services already provided by
Remedent to Den-Mat, which included, without limitation, support and development
of the Tray Technology and advice regarding and improvements to the Intellectual
Property licensed to Den-Mat pursuant to this Agreement, and other legal and
valuable consideration, during the term of this Agreement, Den-Mat shall pay to
Remedent a consulting fee (the “Consulting Fee”)
equal to [***] of the
aggregate Net Revenue received by Den-Mat from the sale of Unit/Teeth and any
Tray that may be associated with the sale of Unit/Teeth, whether or not such
sales utilized the Intellectual Property licensed under this
Agreement.  For purposes of this Section 6.3, a sale
shall be deemed to have been made by Den-Mat at the time the related revenue is
recognized by Den-Mat for its internal accounting purposes (in accordance with
GAAP), and “Net Revenue” shall mean the amount charged per Unit/Tooth and its
associated Tray, if any, as it is invoiced to the end customer from Den-Mat's
perspective (e.g., the
dentist, group practice corporation, distributor), net of any returns,
discounts, special pricing, rebates or additional reasonable price
deductions.  Within sixty (60) days after the end of each calendar
quarter, Den-Mat shall deliver to Remedent a certified statement from an officer
of Den-Mat setting forth (a) the total amount of Den-Mat sales of Unit/Teeth and
any associated Trays during such quarter, and (b) a calculation of the
Consulting Fee payable to Remedent under this Section
6.3.  Concurrently with delivering such statement, Den-Mat
shall pay to Remedent the amount of the Consulting Fee set forth on such
statement.  An advance of $25,000.00 against the Consulting Fees shall
be paid to Remedent upon execution of this Amendment, which amount shall be
promptly refunded to Den-Mat if this Amendment does not become binding on or
before the end of the Option Period (as defined below).”

    

    2.10 Sections
7.1, 7.2, 7.3, 7.4, 7.5 and 7.6 are hereby deleted in their
entirety.  Den-Mat shall order and purchase from Remedent such
quantities of the Products as it may desire, subject to acceptance of such
orders by Remedent, at such price and upon such terms and conditions as the
Parties may mutually agree.  Except as the Parties may hereafter
mutually agree, Den-Mat shall have no obligation to purchase from Remedent, and
Remedent shall have no obligation to sell to Den-Mat, any Products.

     

    2.11 Section
8.1 is hereby amended to delete the entire section except for the first sentence
thereof.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    2.12 On the
90th
day following the Amendment No. 2 Effective Date, Section 8.5 shall be deleted
in its entirety without further action by the Parties.

     

    2.13 Section
11.1 is hereby amended to (a) delete the words “the end of the Exclusivity
Period” in the second line thereof and inserting in lieu thereof the following
words: “the termination of this Agreement” and (b) delete the following words in
the last two lines thereof: “and 7.5.1., but shall not
relieve Den-Mat of its financial obligations to make the minimum payments it is
required to make to Remedent during any unexpired Guaranty Period”.

     

    2.14 Section
11.2.1 is hereby amended and restated in its entirety to read as
follows:

     

    “Subject
to Section
11.2.3, if a Change of Control is consummated at any time prior to
termination of this Agreement, the Exit Fee shall equal [***]

     

    2.15  Section
11.3.1 is hereby amended and restated in its entirety to read as
follows:

     

    “Consulting Fees
Terminate.  If the Exit Fee is paid to Remedent, the obligation
to pay Consulting Fees to Remedent pursuant to Section 6.3 shall
terminate effective as of the effective date of such Change of Control and (b)
the amount of any Consulting Fees paid by Den-Mat to Remedent pursuant to Section 6.3 after the
effective date of such Change of Control shall either be offset against the
payment by Den-Mat of the Exit Fee or directly refunded by Remedent to Den-Mat
concurrently with payment of the Exit Fee.”

    

    2.16 Section
13.3 is hereby deleted in its entirety.

     

    2.17 Section
16.2.4 is hereby amended to provide that, concurrently with the execution of
this Amendment, Remendent shall deliver to Den-Mat revised Non-Competition
Agreements in the form approved by Den-Mat duly executed by Guy De Vreese and
Evelyne Jacquemyns.

     

    2.18 Annex A
to Amendment No. 1 dated August 11, 2009, is hereby amended to provide that the
term “Prego System Technology” includes, without limitation, the “Octoclip” tray
technology developed by Remedent, that the term “Products” includes any products
manufactured utilizing the Octoclip tray technology, and that the Octoclip Tray
Technology and Prego System Technology are part of the Intellectual Property
licensed to Den-Mat under the 2009 Agreement.

     

    2.19 Schedule
2.3.1 is hereby amended to expand the definition of “Additional Excluded
Markets” to include the following countries: Australia, Belgium, France and
United Arab Emirates.

     

    3. Miscellaneous.

     

    3.1 Binding
Effect.  This Amendment shall be binding upon and inure to the
benefit of the Parties and their respective successors and permitted
assigns.  Except as modified hereby, the 2009 Agreement shall remain
in full force and effect.  

     

    3.2 Headings.  The
headings contained in this Amendment are for reference purposes only and shall
not in any way affect the meaning or interpretation of this Agreement.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    3.3 Counterparts.  This
Amendment may be executed in one or more counterparts, all of which will be
considered one and the same agreement and will become effective when one or more
counterparts have been signed by each of the Parties and delivered to the other
Parties, regardless of whether all of the Parties have executed the same
counterpart.  Counterparts may be delivered via facsimile, electronic
mail (including pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes. 

     

    3.4 Governing
Law.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES SHALL BE GOVERNED BY, CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW
RULE THAT WOULD CAUSE THE APPLICATION OR THE LAWS OF ANY JURISDICTION OTHER THAN
THE INTERNAL LAWS OF THE STATE OF NEW YORK TO THE RIGHTS AND DUTIES OF THE
PARTIES.

     

    3.5 Den-Mat
Option.  In consideration of the advance being made by Den-Mat
to Remedent concurrently herewith, in accordance with Section 2.9 of this
Amendment, and other good and valuable consideration, the receipt and
sufficiency whereof are hereby acknowledged, Remedent hereby grants to Den-Mat
an option to enter into this Amendment at any time during the thirty (30) day
period beginning on the Amendment No. 2 Effective Date (the “Option
Period”).  Remedent agrees that it may not revoke or rescind its
execution and delivery of this Amendment prior to the end of the Option Period,
and that if Den-Mat delivers (by fax, email or personal delivery) a
counter-signed copy of this Amendment on or before the last day of the Option
Period, this Amendment shall then become fully binding upon and enforceable
against the parties hereto with effect from the Amendment No. 2 Effective
Date.       

     

    

     

    [remainder
of page intentionally left blank; signature page follows]

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    IN
WITNESS WHEREOF, Remedent Nevada, Remedent Belgium and Den-Mat, by their
respective authorized representatives set forth below, have signed this
Amendment No. 2 as of the Amendment No. 2 Effective Date.

     

    
       

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	      
                                      REMEDENT,
      INC.

                                      “Remedent
      Nevada”

                                       

                                    	 	 	      
                                      REMEDENT,
      N.V.

                                      “Remedent
      Belgium”

                                    	 
	By:    	
                                       

                                    	 	By:  	
                                       

                                    	 
	 	 	 	 	 	 
	Name: 	
                                       

                                    	 	Name: 	
                                       

                                    	 
	 	 	 	 	 	 
	Title:	
                                       

                                    	 	Title: 	
                                       

                                    	 

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

       

      
        
           

        

      

      
        
          
            
              
                	      
                              
                          DEN-MAT
      HOLDINGS, LLC

                          “Den-Mat”

                        

                         

                      	 	 	      
                         

                      	 
	By:    	
                         

                      	 	 	
                         

                      	 
	 	 	 	 	 	 
	Name: 	
                         

                      	 	 	
                         

                      	 
	 	 	 	 	 	 
	Title:	
                         

                      	 	   	
                         

                      	 

              

            

          

        

      

      
 

      
        
           

        

        
          6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]